孕激素预处理卵巢刺激与GnRH类似物在辅助生殖中的系统评价与荟萃分析
该系统评价与荟萃分析纳入20项随机对照试验共4430名女性,比较孕激素预处理卵巢刺激(PPOS)与GnRH拮抗剂和/或激动剂在辅助生殖中的效果与安全性。与GnRH拮抗剂相比,PPOS的活产率更高(RR 1.13,95%CI 1.02-1.25;P=0.02;中等确定性),获卵数更多(MD 0.88,95%CI 0.27-1.50;P=0.005;低确定性),且未报告中重度卵巢过度刺激综合征(OHSS)事件。
要点
- 与GnRH拮抗剂相比,PPOS活产率更高(RR 1.13;95%CI 1.02-1.25;P=0.02;中等确定性)
- PPOS获卵数多于GnRH拮抗剂(MD 0.88;95%CI 0.27-1.50;P=0.005;低确定性)
- PPOS组未报告中重度OHSS事件,提示安全性较好
核心结论
- 中等至低确定性证据表明,与GnRH拮抗剂方案相比,PPOS在首次胚胎移植周期中获卵数更多且活产率更高。
- PPOS看似安全,分析队列中未观察到重度OHSS病例。
- 鉴于口服给药、较低药物成本及已证实的疗效,对于不计划新鲜胚胎移植的女性,PPOS是GnRH类似物的可行且可能更优的替代方案。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Scopus、Web of Science及主要临床试验注册库,从建库至2025年11月11日。
- 纳入20项随机对照试验,共4430名参与者。
- 比较PPOS(如醋酸甲羟孕酮、地屈孕酮、微粒化孕酮)与GnRH拮抗剂和/或GnRH激动剂。
- 主要结局为每名随机化女性的活产率;次要结局包括临床妊娠率、提前LH峰、中重度OHSS、取卵取消率及获卵数。
- 采用随机效应荟萃分析计算相对风险(RR)和均数差(MD)及95%CI,使用GRADE评估证据确定性。
主要发现
- 与GnRH拮抗剂相比,PPOS活产率显著更高(RR 1.13;95%CI 1.02-1.25;P=0.02;中等确定性);排除高偏倚风险研究后敏感性分析仍稳健(RR 1.11;95%CI 1.00-1.23;P=0.05)。
- 与GnRH拮抗剂相比,PPOS获卵数更多(MD 0.88;95%CI 0.27-1.50;P=0.005;低确定性)。
- PPOS与GnRH拮抗剂在取卵取消率(RR 0.82;95%CI 0.42-1.57;P=0.55;低确定性)和提前LH峰(RR 0.49;95%CI 0.05-4.94;P=0.54)上无显著差异。
- 10项研究中两组均未报告中重度OHSS事件。
- PPOS与GnRH激动剂相比,活产率(RR 0.97;95%CI 0.74-1.26;P=0.80;低确定性)、中重度OHSS(RR 0.14;95%CI 0.01-2.74;P=0.20;极低确定性)及获卵数(MD 0.91;95%CI -0.55至2.37;P=0.22;低确定性)均无显著差异,两组提前LH峰和取卵取消均为零事件。
关键数值与推荐
- PPOS vs GnRH拮抗剂:活产率RR 1.13(95%CI 1.02-1.25;P=0.02;中等确定性);获卵数MD 0.88(95%CI 0.27-1.50;P=0.005;低确定性)。
- PPOS vs GnRH激动剂:活产率RR 0.97(95%CI 0.74-1.26;P=0.80;低确定性);中重度OHSS RR 0.14(95%CI 0.01-2.74;P=0.20;极低确定性)。
- PPOS vs GnRH激动剂+拮抗剂:活产率RR 1.01(95%CI 0.80-1.27;P=0.93;极低确定性)。
- PPOS组与GnRH拮抗剂组在10项研究中均未报告中重度OHSS事件。
临床怎么用
- 对于不计划进行新鲜胚胎移植的女性,PPOS可作为GnRH类似物的可行替代方案,可能提高活产率和获卵数。
- PPOS口服给药方便且药物成本较低,在临床决策中可考虑其经济性与依从性优势。
- 现有证据确定性为中等至低,临床应用中需结合患者个体情况并关注证据不确定性。
局限性
- 无研究处于总体低偏倚风险;13项研究存在一些担忧,7项为高偏倚风险。
- INSPECT-SR工具在5项研究中识别出严重的可信度问题。
- 部分比较(如与GnRH激动剂或联合方案)的证据确定性为低至极低,且事件数少。
- 主要结局活产率的证据确定性为中等,获卵数等次要结局确定性较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness and safety of progestogen-primed ovarian stimulation (PPOS) vs gonadotropin-releasing hormone (GnRH) antagonists and/or agonists for women undergoing assisted reproduction. METHODS: PubMed, Scopus, Web of Science and major clinical trial registries were searched from inception until 11 November 2025 for randomized controlled trials (RCTs) comparing PPOS (e.g. medroxyprogesterone acetate, dydrogesterone, micronized progesterone) with GnRH antagonists and/or GnRH agonists in women undergoing ovarian stimulation for in-vitro fertilization or intracytoplasmic sperm injection using their own oocytes, for oocyte donation or for fertility preservation. The primary outcome was the live-birth rate per woman randomized. Secondary outcomes included rates of clinical pregnancy, premature luteinizing hormone (LH) surge, moderate/severe ovarian hyperstimulation syndrome (OHSS) and oocyte pick-up (OPU) cancelation, and the number of oocytes retrieved. Risk of bias was assessed using the Cochrane revised Risk of Bias (RoB 2) tool and trustworthiness was evaluated using the INveStigating ProblEmatic Clinical Trials in Systematic Reviews (INSPECT-SR) tool. We performed random-effects meta-analyses to calculate relative risk (RR) and mean difference (MD) with 95% CI, as appropriate. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Twenty RCTs involving 4430 participants were included. No study was at low overall risk of bias; 13 had some concerns and seven were at high risk. INSPECT-SR identified serious trustworthiness concerns in five studies. PPOS was compared with GnRH antagonists in 17 studies, GnRH agonists in two studies and a combined GnRH agonist + antagonist regimen in one study. Compared with GnRH antagonists, PPOS was associated with a significantly higher live-birth rate (RR, 1.13 (95% CI, 1.02-1.25); P = 0.02; moderate certainty). This finding remained robust on sensitivity analysis excluding the study with a high risk of bias (RR, 1.11 (95% CI, 1.00-1.23); P = 0.05). PPOS was also associated with a higher number of oocytes retrieved compared with GnRH antagonists (MD, 0.88 (95% CI, 0.27-1.50); P = 0.005; low certainty). There were no significant differences in the rates of OPU cancelation (RR, 0.82 (95% CI, 0.42-1.57); P = 0.55; low certainty) or premature LH surge (RR, 0.49 (95% CI, 0.05-4.94); P = 0.54) between groups. No moderate/severe OHSS events were reported in either group across 10 studies. For the comparison of PPOS vs GnRH agonists, there were no significant differences in live-birth rate (RR, 0.97 (95% CI, 0.74-1.26); P = 0.80; low certainty), moderate/severe OHSS (RR, 0.14 (95% CI, 0.01-2.74); P = 0.20; very low certainty) or number of oocytes retrieved (MD, 0.91 (95% CI, -0.55 to 2.37); P = 0.22; low certainty), with zero events reported for premature LH surge and OPU cancelation in both groups. In the comparison of PPOS vs combined GnRH agonist + antagonist regimen, there were no significant differences in live-birth rate (RR, 1.01 (95% CI, 0.80-1.27); P = 0.93; very low certainty) or OPU cancelation (RR, 0.79 (95% CI, 0.38-1.67); P = 0.54; very low certainty), with no premature LH surges reported. CONCLUSIONS: Current evidence of moderate-to-low certainty suggests that PPOS results in a higher number of oocytes and a higher live-birth rate in the first embryo-transfer cycle compared with a GnRH antagonist protocol. PPOS appears safe, with no case of severe OHSS observed across the analyzed cohorts. Given its oral administration, lower drug cost and demonstrated efficacy, PPOS represents a viable and potentially superior alternative to GnRH analogs for women undergoing ovarian stimulation for whom fresh-embryo transfer is not intended. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Martins WP, Nastri CO. Progestogen-primed ovarian stimulation vs GnRH antagonists and/or agonists for women undergoing assisted reproduction: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2026. PMID: 42425545. doi:10.1002/uog.70267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。